NCT02913443已完成1 期
A Multi-Center, Open Label, Phase I, Dose Finding and Expansion Study of RO7051790 Administered Orally in Patients With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 8
- 主要终点
- Number of Participants with Dose-Limited Toxicities (DLTs)
研究概览
简要总结
This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC. This dose escalation and expansion study plans to determine the maximum tolerated dose and/or optimal biological dose as a recommended Phase 2 dose for RO7051790, based on the safety, tolerability, pharmacokinetic and pharmacodynamic profiles observed after oral administration of RO7051790.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Life expectancy greater than or equal to (>=) 12 weeks
- •Participants must have histologically or cytologically confirmed diagnosis of SCLC
- •Participants must have recurrent or refractory disease after receiving at least one prior platinum-containing chemotherapy regimen, or standard therapy is refused or not suitable. For participants in Canada: participants should also not be suitable for treatment with topotecan hydrochloride
- •Acute toxicities from any prior treatment, surgery, or radiotherapy must be National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade less than or equal to (<=) 1
- •Measureable disease per RECIST v1.1 prior to administration of study medication
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- •Adequate bone marrow function
- •Adequate renal function
- •Participant must be able to swallow and retain orally administered study treatment
- •Women of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for a period of time after the last dose of study treatment
排除标准
- •Active malignancy other than SCLC within the previous 5 years
- •Participants who have received radiotherapy less than 2 weeks prior to first dose of study medication
- •Surgical procedure or clinically significant trauma within 2 weeks of first dose of study treatment
- •Treatment with any investigational agent <=3 weeks prior to first dose of study treatment
- •Participants with gastrectomy or pre-existing gastrointestinal disorders that may interfere with the proper absorption of the drug(s), as per conclusion of the clinical Investigator
- •Participants medicated with anti-depressants reported to have lysine-specific histone demethylase 1A (KDM1A)/lysine (K)-specific demethylase 1A (LSD1) inhibitory activity (such as tranylcypromine or phenelzine) within 28 days of treatment start
- •History of allergic reactions attributed to components of the formulated product(s)
- •History of seizure disorders
- •Participants with untreated central nervous system metastases, or history of previously treated disease. Participants must have stable hematological parameters, satisfying eligibility, platelet count must be stable for >=2 weeks prior to study drug administration
- •Participants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
- •Participants with evidence of electrolyte imbalance
- •Participants who are pregnant or breastfeeding
- •Participants who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
- •Participants with known bone marrow disorders which may interfere with bone marrow recovery or participants with delayed recovery from prior chemoradiotherapy
- •Participants with known coagulopathy, platelet disorder or history of non-drug-induced thrombocytopenia
- •Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)-positive participants with active infection
- •Use of strong Cytochrome P450 3A4 (CYP3A4) inducers while on study medication
- •Participants with abnormal hepatic function
- •Participants with history of clinically significant bleeding, specifically any history of intracranial hemorrhage/hemorrhagic cardiovascular accident (CVA), or participants with gastrointestinal bleeding within the 12 months prior to study entry
- •Participants receiving therapeutic anti-coagulation or anti-platelet (anti-aggregant) therapies, except for therapeutic enoxaparin or low dose aspirin. Use of subcutaneous heparin prophylaxis, including low molecular weight heparin is also permitted
研究组 & 干预措施
Introductory Cohort - 400 μg RO7051790
Experimental
Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
干预措施: RO7051790 (Drug)
Dose Escalation - 1000 μg RO7051790
Experimental
1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
干预措施: RO7051790 (Drug)
Dose Escalation - 1300 μg RO7051790
Experimental
1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
干预措施: RO7051790 (Drug)
Dose Escalation - 1900 μg RO7051790
Experimental
1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
干预措施: RO7051790 (Drug)
结局指标
主要结局
Number of Participants with Dose-Limited Toxicities (DLTs)
时间窗: First treatment cycle (21 days)
DLTs were to be assessed based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. DLTs were at least possibly related to RO7051790 and had to meet any one of the following criteria: Grade≥4 neutropenia lasting \>7 days; Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding; Grade≥4 anemia; Febrile neutropenia; Grade≥3 elevation in serum hepatic transaminase lasting \>7 days; Grade≥3 elevation of serum bilirubin; and Grade≥3 non-hematologic, non-hepatic adverse event (with few exceptions).
Percentage of Participants with Adverse Events
时间窗: Baseline up to approximately 18 weeks
次要结局
- Minimum Observed Plasma Trough Concentration (Cmin) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days))
- Percentage of Participants with Best Confirmed Overall Response(Time from first study treatment to the time of progression or death from any cause, whichever occurs first (Assessed every 6 weeks up to approximately 18 weeks))
- Percentage of Participants with Objective Response According to RECIST(Time from first study treatment to the time of progression or death from any cause, whichever occurs first (assessed every 6 weeks up to approximately 18 weeks))
- Progression-Free Survival (PFS) According to RECIST v1.1(Time from first study treatment to the time of progression or death from any cause, whichever occurs first (assessed every 6 weeks up to approximately 18 weeks))
- Overall Survival (OS)(Time from first study treatment to death from any cause (up to approximately 12 months))
- Duration of Response According to RECIST v1.1(Time from first occurrence of a documented objective response to the time of progression or death from any cause, whichever occurs first (assessed every 6 weeks up to approximately 18 weeks))
- Plasma Decay Half-Life (t1/2) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
- Area Under the Curve from Time Zero to End of Dosing Interval (AUCtau) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
- Apparent Oral Clearance (CL/F) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
- Apparent Volume of Distribution (Vz/F) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
- Accumulation Ratio (RA) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
- Maximum Observed Plasma Concentration (Cmax) of RO7051790(Predose (0 hours [hrs]) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1,2,4,6,8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8,12,15,19)
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of RO7051790(Predose (0 hrs) on Day 1 of every cycle until end of treatment (up to 18 weeks, each cycle is 21 days); Cycles 1 and 2: 1, 2, 4, 6, 8 (only in Cycle 1) hrs postdose on Day 1 and on Days 2 (only in Cycle 1), 4, 5 (only in Cycle 1), 8, 12, 15, 19)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Trial Of IW001 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT01199887ImmuneWorks30
招募中
1 期
A Study of SHR-3821 Injection in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT06618651Suzhou Suncadia Biopharmaceuticals Co., Ltd.162
终止
1 期
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05036291Ningbo Newbay Technology Development Co., Ltd25
已完成
1 期
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourRecurrent GlioblastomaBrain TumorNCT00503204AstraZeneca20
已完成
1 期
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsHigh-grade Serous Ovarian CancerSolid TumorsNUT Midline CarcinomaTriple-Negative Breast CancerNCT02307240Curis, Inc.43